Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial
Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.